Contact Us | 1.617.500.7867 Overview Leadership Careers Benefits Contact Us Rare Disease Day EU Payment Disclosures 2014 EU Payment Disclosures 2013 EU Payment Disclosures What is HoFH? Development Programs JUXTAPID® MYALEPT® Contact Global Medical Information Overview Clinical Trials Physician Resources Global Medical Information Press Releases Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. 6.16.15 - Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety 5.4.15 - Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results 4.9.15 - Jorge Plutzky, M.D., Appointed to Aegerion Pharmaceuticals' Board of Directors 3.30.15 - Aegerion Pharmaceuticals Reaches Agreement with Sarissa Capital all news | subscribe to feed 2014 Annual Report Symbol: AEGR Last Price: 13.560 Change: 0.370 Volume: 1107900 Quote Date: 10/2/2015 4:00:01 PM This page is intended exclusively for U.S. audiences. © 2012 Aegerion Pharmaceuticals, Inc. All rights reserved. AEGR/Global/167 07-14 Terms of Use | Contact Us | Site Map